Loss of cryptochrome reduces cancer risk in p53 mutant mice by Ozturk, Nuri et al.
Loss of cryptochrome reduces cancer risk in
p53 mutant mice
Nuri Ozturk1, Jin Hyup Lee1, Shobhan Gaddameedhi, and Aziz Sancar2
Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, NC 27599
Contributed by Aziz Sancar, December 22, 2008 (sent for review November 13, 2008)
It is commonly thought that disruption of the circadian clock
increases the cancer incidence in humans and mice. However, it
was found that disruption of the clock by the Cryptochrome (Cry)
mutation in mice did not increase cancer rate in the mutant mice
even after exposing the animals to ionizing radiation. Therefore, in
this study we tested the effect of the Cry mutation on carcinogen-
esis in a mouse strain prone to cancer because of a p53 mutation,
with the expectation that clock disruption in this sensitized back-
ground would further increase cancer risk. Paradoxically, we find
that the Cry mutation protects p53 mutant mice from the early
onset of cancer and extends their median lifespan 50%, in part by
sensitizing p53 mutant cells to apoptosis in response to genotoxic
stress. These results suggest alternative therapeutic approaches in
management of cancers associated with a p53 mutation.
apoptosis  circadian clock  DNA repair
C ircadian rhythm is the cyclical change in the physiology andbehavior of organisms with a periodicity of 24 h (1). This
rhythm is generated by a molecular clock that is present in
virtually all cells in humans and mice. The peripheral clocks
throughout the organism are coordinated by a master clock
located in the suprachiasmatic nuclei (SCN) in the hypothala-
mus. Clock disruption by environmental or genetic factors has
been implicated in a number of pathologic conditions (2–9). Of
interest, several epidemiologic studies and, more recently, some
studies with animal model systems have suggested that circadian
clock disruption predisposes humans and mice to cancer (5, 6).
The significant progress that has been made recently in
understanding the circadian clock at the molecular level (10, 11)
has provided the conceptual and technical tools for investigating
the clock disruption-cancer connection at a mechanistic level.
The mammalian circadian clock is generated by a transcription-
translation feedback loop (TTFL): The transcriptional activators
Clock and BMal1 proteins make a heterodimer that binds to the
promoter of the transcriptional repressor genes Cryptochrome 1
and 2 (Cry1 and Cry2) and Period 1 and 2 (Per 1 and Per2) and
induces their transcription. The Cry and Per proteins make
heterodimers, which, after a time lag, inhibit the Clock-BMal1
complex and hence their own transcription (10–12). The time
delay between the synthesis of the Per and Cry and their action
as repressors is a key factor in generating an oscillatory pattern
of expression of these proteins and of the clock controlled genes
that produce the circadian phenotype (12). Although this basic
circuitry is consolidated by posttranslational modifications and
by interfacing with other transcriptional circuits, Clock, BMal1,
Crys and Pers are considered the core clock genes. Hence studies
aimed at investigating the clock disruption-cancer connection
have either targeted these genes or used animals in which the
master circadian clock in the SCN was surgically destroyed.
It was found that in SCN-lesioned arrhythmic mice, subcutane-
ous (s.c.) implants of 2 different types of cancers grew at a faster rate
than in the controls with normal circadian rhythm (13), leading to
the conclusion that circadian disruption at the organism level
facilitated tumor growth. This conclusion was reinforced by a study
with Per2 mutant mice. It was reported that these mice developed
spontaneous and ionizing radiation (IR)–induced lymphomas at a
much higher rate than the wild-type controls (14). These studies,
combined with the epidemiological data on humans, led to the
generalization that circadian clock disruption by any means pre-
disposes animals to cancer. However, subsequent work with mice
with mutations in either the negative arm (Cry) or the positive arm
(Clock) of the TTFL did not support this generalization. It was
found that Cry1/Cry2/ (15) and clock/clock (16) mutant mice
were indistinguishable from wild-type mice with respect to the
incidence of spontaneous and IR-induced tumors. Thus, it was
concluded that not the circadian clock disruption in itself but the
manner in which the clock is disrupted is more germane to a
potential increase in cancer susceptibility. However, it was also
conceivable that the studies with the Cry and Clock mutants were
inconclusive with respect to the long-term effects of circadian
disruption, in particular when clock disruption occurs in a cancer
sensitized genetic background such as occurs in animals with a
mutation in either an oncogene or a tumor suppressor. To address
this particular issue we decided to combine the Cry mutation with
the p53 mutation.
The tumor suppressor p53 is mutated in nearly half of human
cancers (17). In mouse models for human cancers, often p53
mutations are combined with mutations in other genes that are
suspected to play a role in cancer development (18). Commonly,
such combinations increase the incidence of cancer that is
already quite high in p53 mutant mice (19–22). Paradoxically, we
found that the Cry mutation delays cancer onset in p53 mutant
mice and increases the median lifespan of these mice 1.5-fold.
This finding raises the possibility of cancer management by
interfering with cryptochrome function at the level of the whole
organism or selectively in cancer tissue.
Results
Generation of p53/Cry1/Cry2/ Mice. We crossed p53/ mice
in C57BL/6J background (23) with Cry1/Cry2/ mice in the
same background (15), and by interbreeding the progeny of this
cross we obtained the p53/Cry1/Cry2/ mice and mice with
other combinations of p53 and Cry mutations. As is well known
for p53/ mice (24), there was a strong bias for males among the
triple knockout progeny (male:female  19:2). Fig. 1A shows the
genotyping of the mutants by genomic PCR and immunoblotting
for p53, Cry1, and Cry2 proteins. Fig. 1B shows that a compar-
ison of 8-week old p53/ and p53/Cry1/Cry2/mice
reveals no obvious physical differences between the 2 mice
except the triple knockouts weigh 20% less than the p53/
mice, an observation that has been made previously in compar-
ing Cry1/Cry2/ with their wild-type littermates (25).
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Cancer Incidence in Cryptochrome-deficient p53/ Mice. It is well-
established that p53/ mice develop cancers, mostly lymphomas
and lymphosarcomas, with a median age of 20 weeks in
C57BL/6J background (18, 24). Combination of p53/ with a
mutation in a tumor suppressor such as Rb (20) or with an
up-regulated oncogene, such as ras or myc (19, 22), increases the
incidence of cancer. Surprisingly, even combinations of p53/
with mutations that were expected to reduce cancer incidence
did not afford protection to p53/ mice (26).
Hence it appears that p53 null mutations have a rather
penetrant phenotype that may be amplified under certain cir-
cumstances but that rarely, if ever, can be overcome by other
mutations. Against this background then, the effect of Cry null
mutations on p53/ mice was surprising. As seen in Fig. 2, the
age adjusted incidence of cancer in p53/Cry1/Cry2/ mice
was significantly lower than that of p53/ mice and the median
lifespan of the triple knockout mice (28.1 weeks) was nearly
1.5-fold that of the p53/ mice (18.6 weeks). Even mutating 3
out of the 4 Cry genes provided some protection as apparent
from a lifespan of 23.1 weeks for p53/Cry1/Cry2/ and
p53/Cry/Cry2/ mice (Fig. 2). It is known that a single Cry
gene provides partial molecular and behavioral rhythmicity in
mice (27–29). Thus, it appears that reducing the level of or
eliminating cryptochrome imparts protection from cancer death
to p53/ mice in a manner proportional to the degree of
cryptochrome reduction.
However, the triple knockout mice do eventually succumb to
death from cancer. Histopathological examination reveals that
these mice have a delayed development of the typical lympho-
blastic lymphomas seen in p53/ mice. Histopathological types
of some of the tumors (such as non-lymphoblastic lymphoma or
histiocytic sarcoma) are those associated with late developing
lymphomas in p53/ mice or commonly observed in aged mice
(Fig. 3). This raises the question as to why the triple knockout
mice have a lower age-adjusted incidence of cancer and longer
lifespan than the p53/ mice. This question is addressed below.
Molecular Analysis of Carcinogenesis in p53/ Mice Without Crypto-
chrome. The reduced rate of cancer incidence in, and the longer
lifespan of, the triple knockout mice relative to the p53/ mice
by the Cry mutation could be due to either prevention (or delay)
of malignant transformation of p53/ cells or activation of some
Fig. 1. Genotyping and physical appearance of mice used in this study. (A) Isolated skin fibroblasts from 2 age-matched mice of p53/ (p53-KO) and
p53/Cry1/Cry2/ (TRI-KO) genotypes were used for analysis. (Left) Genotyping by genomic PCR. For each gene, an anchor and a knockout or wild-type
allele-specific primers were used. Genomic DNA from the tail of a triple heterozygous mouse was used as a positive control for each set of primer pairs. Lane
1, DNA from a triple heterozygous mouse; lanes 2 and 3, DNA from 2 p53-KO fibroblasts; lanes 4 and 5, DNA from 2 TRI-KO fibroblasts; lane 6, no genomic DNA.
M, molecular size markers. (Right) Immunoblot of fibroblast lysates. 50 g of protein from lysates of cultured fibroblasts were used for immunoblotting. Lanes
1 and 2, lysates from immortalized Cry1/Cry2/ and wild-type (WT) fibroblasts, respectively (15); lanes 2 and 3, lysates from fibroblasts shown in Left lanes
2 and 3; lanes 5 and 6, lysates from fibroblasts shown in Left lanes 4 and 5. A protein band cross-reacting with Cry2 antibody (indicated by *) is shown as a loading
control. (B) Physical appearance of mutant mice. TRI-KO (top) and p53-KO (bottom) at 8 weeks of age appear anatomically normal but the TRI-KO mutants are
smaller and weigh 20% less than the p53-KO mice.
Fig. 2. Mutations of Cryptochromes in p53/ mice reduces age adjusted
tumor incidence. Kaplan–Meier survival analysis (log-rank test) of the time of
death with evidence of tumors showed significant differences between
p53/ and p53/Cry1/Cry2/ or p53/Cry1/Cry2/ (P  0.0148), be-
tween p53/ and p53/Cry1/Cry2/ (P  0.0001), and between p53/
Cry1/Cry2/ or p53/Cry1/Cry2/ and p53/Cry1/Cry2/ (P 
0.0043). There was no significant survival difference between p53/Cry1/
Cry2/ (n  19) and p53/Cry1/Cry2/ (n  9) (P  0.0638) and hence
these groups were combined in our analysis.
Fig. 3. Histopathological analyses of mice with tumors. Both p53-KO and
TRI-KO mice develop thymic lymphoma, often coupled with peripheral lymph-
adenopathy. In addition, TRI-KO mice also present abdominal distension due
to massive lymphoma and other sarcomas in the liver and spleen typically seen
in older p53-KO mice. (A) (Left) A representative 28-week old p53-KO mouse
with thymic lymphoblastic lymphoma. (Right) A hematoxylin and eosin–
stained section of thymic lymphoma from this mouse. (B) (Left) A represen-
tative TRI-KO mouse at 36 weeks of age exhibiting an abdominal mass in
addition to the thymic lymphoma. (Right) A hematoxylin and eosin–stained
section of thymic lymphoma from this mouse.
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signaling pathways that eliminate transformed cells and that
have been abrogated in p53/ cells. To differentiate between
these possibilities, we isolated skin fibroblasts from p53/ and
p53/Cry1/Cry2/ mice and tested them for a variety of cell
growth and proliferation endpoints. p53 is a multifunctional
protein that prevents cancer by promoting cell cycle arrest,
senescence, or apoptosis in response to genotoxic stress and to
proliferative signals such as those given by oncogenes (17, 18).
Hence, we tested the cell lines from the triple knockout mutant
mice to find out which of these response reactions lost by p53
mutation may have been restored by the Cry mutation. First, we
analyzed the growth properties of skin fibroblasts isolated from
p53/ and the triple knockout mutants. Fig. 4A shows that the
fibroblasts of the 2 genotypes grow at the same rate (Upper), and,
when tested for multiple passages, they appear to be already
immortalized, in contrast to the fibroblasts from wild-type mice,
which slow down dividing after 5 doublings (Lower). In parallel
with these findings the p53/ and the triple knockout fibroblasts
show no evidence of senescence as measured by the senescence-
associated  galactosidase assay, while normal fibroblasts se-
nesce under these conditions (Fig. 4B). Thus, we conclude that
elimination of cryptochrome does not affect the proliferative
phenotype of p53/ cells nor does it restore the senescence
phenotype that has been lost in these cells.
Then, we tested the primary skin fibroblasts for foci formation
induced by Ras to probe for oncogenic transformability of the
fibroblasts (30). The data shown in Fig. 4C reveal that while
normal fibroblasts fail to produce Ras-induced foci, 2 indepen-
dent isolates of both p53/ and p53/Cry1/Cry2/ fibro-
blasts produce foci at the same frequency upon transfection with
the Ras oncogene. We conclude that removal of cryptochrome
in a p53/ background does not prevent immortalization of the
cell nor does it prevent its oncogenic transformation. Therefore,
the reduced incidence of overt cancers and the increased lifespan
of the triple knockout mice may have been caused by an
abnormal response to inevitable genotoxic stress, to which
oncogenically transformed cells are subjected. In the following
series of experiments we tested for this response.
Genotoxic Responses of p53/ and Cryptochromeless p53/ Skin
Fibroblasts. To analyze the contribution of cryptochrome to the
response of p53/ cells to genotoxic stress, we irradiated p53/
and p53/Cry1/Cry2/ mouse skin fibroblasts with UV and
measured clonogenic survival, DNA repair, DNA damage
checkpoint response, and apoptosis. We found that the elimi-
nation of cryptochrome increases the sensitivity of p53/ cells
to killing by UV (Fig. 5). To determine whether the increased
sensitivity was due to reduced repair capacity, defective DNA
damage checkpoint response, or enhanced apoptosis, we ana-
lyzed these responses to DNA damage in p53/ and triple
knockout cell lines. We found that elimination of cryptochrome
does not affect the nucleotide excision repair capacity of the
fibroblasts as measured by cyclobutane thymine dimer removal
in vivo (Fig. 6A) and (6–4) photoproduct removal in vivo (data
not shown) and with cell free extracts (Fig. 6B). Similarly,
although the Cry deletion led to an increase in the level of the
antimitotic kinase Wee1, as reported previously (15, 32, 33) (Fig.
7A), it had no effect on the G2/M checkpoint response, as
reported previously (15), nor on normal functioning of the
ATR 3 Chk1 and ATM 3 Chk2 signaling pathways (Fig. 7B).
In contrast, we found that p53/Cry1/Cry2/ cells are more
susceptible to UV-induced apoptosis than p53/ cells as mea-
sured by proteolytic cleavage of caspase 3 and Poly (ADP) ribose
polymerase (PARP) (Fig. 7C and D), which likely explains
the increased sensitivity to UV killing of the triple knockout
fibroblasts relative to the p53/ fibroblasts. The potential
significance of these findings to the increased lifespan of the
p53/Cry1/Cry2/ mice relative to p53/ mice is discussed
below.
Discussion
Circadian Cycle and Cell Cycle. The circadian clock and the cell cycle
are 2 global regulatory systems at cellular and organismic levels
Fig. 4. Analyses of p53-KO and TRI-KO fibroblasts for growth, immortalization, senescence, and malignant transformation properties. (A) (Upper) Growth
kinetics of the fibroblasts. Cells were seeded into 6-well plates and counted after incubation for the indicated times. (Lower) Long-term cumulative population
doubling assay for fibroblasts were determined using cells passaged every 3–4 days. Cells were seeded into 6-well plates and counted after 48 h. Population
doublings were calculated at different passages and plotted. Fibroblasts from a wild-type mouse were maintained for at least 8 passages without any overt
immortalization. (B) Senescence-associated  galactosidase staining (blue) of fibroblasts at late passages (passage 25 for p53-KO and TRI-KO). Wild-type skin
fibroblasts (passage 8) from an age-matched mouse were used as a positive control. (C) Ras-induced oncogenic transformation. Fibroblasts from 2 p53-KO mice
(p53-KO1 and p53-KO2) and 2 triple mutant mice (TRI-KO1 and TRI-KO2) were transfected with Ras pT24pEGFP.N1 () or pEGFP.N1 (-), and colonies were
counted after 19 days. Colony numbers were adjusted to transfection efficiencies, which were quite similar for p53-KO and TRI-KO fibroblasts. WT-MEF, wild-type
mouse embryonic fibroblasts were used as a negative control. Bars indicate standard errors of the mean.











and therefore are expected to interface. Indeed, the systems are
known to interface at a number of critical points. BMal1-Clock
positively regulates the Wee1 antimitotic kinase (15, 32, 33), and
BMal1-Clock or BMal1-NPas2 represses c-Myc transcription
(14). The transcription of c-Myc was reported to be highly
elevated in Per2 mutant mice (because Per2 positively regulates
BMal1 transcription and in the absence of Per2 the BMal1, a
repressor of c-Myc, is down) and the high incidence of IR-
induced lymphoma in these mice was ascribed, at least in part,
to the elevated c-Myc (14). In addition to the circadian cycle-cell
cycle connection at the transcriptional level, the 2 systems
interface at the protein–protein interaction and signal modula-
tion level as well. First, the Timeless protein, which is required
for a robust circadian rhythm in mice (34), directly interacts with
the cell cycle checkpoint proteins ATR and Chk1 such that
down-regulation of Timeless interferes with the ATR 3 Chk1
branch of the DNA damage checkpoint response (35). Second,
Per1 has been reported to interact with both the ATM and Chk2
proteins and to directly participate in the ATM 3 Chk2 DNA
damage signaling pathway (36). Moreover, it has been reported
that Per1 overexpression induces cell death in several cancer cell
lines, presumably by activating the ATM3 Chk2 signaling axis
and arresting cell proliferation and promoting apoptosis (36).
Clearly, these are interesting findings that need further expan-
sion before they can be considered as potential circadian clock-
checkpoint connections that might be exploited in cancer man-
agement.
Circadian Cycle and Cancer. Despite the epidemiological findings
suggesting that disruption of the circadian clock predisposes
humans to cancer (5, 37, 38), currently available data from
mouse model systems reveal a rather conflicting picture. Dis-
ruption of the clock by the Per2 mutation is reported to
predispose mice to cancers (14), but disruption of the clock by
the Cry mutation (which, like the Per2 mutation, affects the
negative arm of the clock TTFL) does not (15), nor does the
mutation of Clock, which affects the positive arm of the circadian
TTFL (16). BMal1 mutants exhibit an early aging phenotype and
die at a relatively young age (16, 39) and, hence, are not suitable
for studying carcinogenesis. Taking into account the data from
Per2, Cry, and Clock mutants, the only conclusion that can be
made at present is that clock disruption per se does not predis-
pose mice to cancers and that these core clock genes must
participate in functions that are unique to each and are separable
from the clock functions of these genes to give rise to such
different phenotypes.
Cancer Management by Clock Disruption. The results presented in
this article taken at face value would suggest that down-
regulating Cry or interfering with Cry function in cancers
associated with p53 null mutations may slow the progression of
cancer and, in combination with other approaches to cancer
treatment, it may increase the success rate of remission. At
present we do not know how the Cry mutation renders onco-
genically transformed p53/ cells more susceptible to apoptosis
and delays the appearance of overt tumors. One possibility
supported by our data is that the deletion of Cry makes the
oncogenically transformed cells more sensitive to apoptotic
signals. Interestingly, even though Wee1 (which is elevated in Cry
mutants) is well known for its effect on mitosis as the enzyme
that phosphorylates and hence inhibits mitotic kinase Cdc2, it
has also been found that it specifically interacts with the SH2
domain of the Crk adaptor protein and, in doing so, activates the
apoptosis signaling cascade both in Xenopus egg extract (40) and
in the human U2OS osteosarcoma line (41). In addition to this
potential role of Wee1 in apoptosis, it is conceivable that the Cry
Fig. 5. Clonogenic survival assay for primary skin fibroblasts from p53-KO
and TRI-KO mice. (Upper) Into 6-well plates, 105, 5  104, and 2  104 cells were
seeded in duplicates, irradiated with UV, and then incubated for 9–10 days
until colonies were readily visible. Colonies were then stained with 5% meth-
ylene blue. (Lower) UV survival curves obtained from 3 experiments including
the 1 shown in Upper. Error bars indicate standard errors of the mean and the
asterisks indicate statistically significant (P  0.01) difference in clonogenic
survival.
Fig. 6. In vivo and in vitro excision repair capacity of p53-KO and TRI-KO
fibroblasts. (A) In vivo repair assay. Fibroblasts of the indicated genotypes
were exposed to a 10 J/m2 UV dose and the level of repair was quantified by
slot-blot with anti-CTD monoclonal antibody. (Left) A representative assay.
(Right) Quantitative analysis of data from 3 independent experiments includ-
ing the 1 shown in Left. The repair kinetics of CTD and of (6–4) photoproducts
(data not shown) of p53/ fibroblasts are in agreement with a previous report
(31). (B) (Left) Removal of (6–4) photoproducts in vitro with cell free extracts
(CFE). Extracts from p53-KO and TRI-KO cell lines were incubated with a 136-bp
substrate (S) containing a (6–4) T-T photoproduct, for the indicated times.
Reaction products were then analyzed on a 10% sequencing gel. The excision
products in the 24–32 nt range are bracketed. Lane 1, substrate without
treatment; lanes 2, 4, 6, and 8, substrates treated with p53-KO fibroblast CFE
for 30, 60, 90, and 120 min; lanes 3, 5, 7, and 9, substrates treated with TRI-KO
CFE for 30, 60, 90, and 120 min. (Right) Quantitative analysis of the excision
from 3 experiments including the 1 shown in Left. Error bars indicate standard
errors of the mean. There was no statistically significant difference (P  0.05
by a 2-sample t test) in the excision activities of the 2 extracts.
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mutation may delay tumorigenesis by affecting non–cellautono-
mous factors, such as altered immune surveillance of tumors. It
is also possible that the Cry mutation reduces tumorigenicity in
p53/ mice by reducing the level of reactive oxygen species that
are known to be elevated in BMal1/ mice (39) and could
conceivably be reduced in Cry mutants. Clearly, further work is
needed to provide mechanistic explanations for the reduction of
cancer risk in p53/ mice by the Cry mutation.
Materials and Methods
Generation of p53/Cry1/Cry2/ Mice. p53/ mice in C57BL/6J background
(23) and Cry1/Cry2/ mice with the same background (15) were used to
obtain p53/ mice, mice with p53/ and single Cry, and the triple knock-
out mice. Most of triple knockouts were generated from crossing p53/
Cry1/Cry2/ males and p53/Cry1/Cry2/ females. Genotyping was
done before the age of 19 days. Genomic DNA was isolated from the tail for
PCR. For each gene, an anchor and a primer specific for knockout or wild-type
sequences were used. PCR products were analyzed on a 1% (wt/vol) agarose
gel. The genotypes of immortalized skin fibroblasts isolated from some of the
mutants were confirmed by immunoblotting.
Isolation of Fibroblasts and Growth Curves. We used skin fibroblasts from 2 age
matched p53/ and triple knockout mice for molecular analyses. Skin patches
from the back of mice at the age of 3 months were taken under sterile
conditions, cut into small pieces, placed into 4 or 6 well-plates, and incubated
1 week to let the fibroblasts migrate into the wells. Fibroblasts were passaged
at least 3 times before using them for any experiment. Wild-type mouse
embryonic fibroblasts were kindly provided by Dr. Norman Sharpless (Univer-
sity of North Carolina). Primary wild-type skin fibroblasts were isolated as
described above, and passaged 8 times without appearance of spontaneously
immortalized clones. For the population doubling (PD) assay, 50  104 cells
were plated into 6-well plates, and counted after 48 h, using a hemocytom-
eter. PD was determined by the formula: PD  Log (Nf/Ni)/Log2, where Nf 
the number of cells counted and Ni  the number of cells seeded. Senescence
associated -galactosidase (SABG) activity was detected using a standard
protocol (42).
Assay for Ras-induced Oncogenic Transformation. Cells were seeded into 10 cm
plates, and transfected with 250 ng of pEGFP-N1 (Clontech), and/or 5 g of Ras
pT24 vector (30) using FuGENE 6 reagent (Roche). The next day, cells were split
into 3 plates, and incubated for 18 days. The plates were stained with Giemsa
and colonies of oncogenically transformed cells were counted visually and the
fraction of transformed cells was normalized for transfection efficiencies
calculated by counting GFP positive cells in each plate. The results shown are
from 3 independent transfections.
Histopathological Analyses. Animals were handled according to the guidelines
of the National Institutes of Health and the University of North Carolina.
Animals with visible tumors or exhibiting severe morbidity were euthanized
with carbon dioxide and fresh tissues were taken for pathological examina-
tion. Parts of some tissues were fixed in 10% buffered formalin, and submitted
to the University of North Carolina School of Medicine Pathology Department
for analysis.
Treatment of Cells with UV Radiation for Survival Assay. Fibroblasts of indicated
genotypes were seeded into 6-well plates at 105, 5  104, and 2  104 cells per
well in duplicates, and exposed to 10 J/m2 of UV (254 nm) radiation from a
germicidal lamp at a fluence rate of 0.5 Jm2s1. After UV treatment, the cells
were washed with PBS and incubated in high-glucose DMEM for 9 to 10 days
until colonies were readily visible. Cells were fixed for 20 min in 3:1 methanol/
acetic acid, rinsed with water, and stained with 5% methylene blue. Colonies
containing  50 cells were scored.
Measurement of DNA Repair Activity In Vivo. Exponentially growing cells were
treated with UV (254 nm) radiation at a dose of 10 J/m2. Cells were harvested
at 0, 6, 12, and 24 h after UV radiation and stored at 20 °C until processing.
Genomic DNA was isolated using the QIAamp DNA Mini kit (Qiagen). Cyclobu-
tane thymine dimers (CTDs) were detected by slot blot using anti-CTD mouse
monoclonal antibody (Kamiya Biomedical) diluted in PBS (1:2,000) containing
0.1% Tween 20 for 16 h at 4 °C, which was followed by incubation with an
anti-mouse antibody-HRP conjugate (43). CTD signals were detected using an
ECL reagent (GE Healthcare). Quantification was performed with ImageQuant
5.2 software (Molecular Dynamics).
Measurement of DNA Repair Activity In Vitro. The excision repair assay (44) was
carried out with a 136-bp DNA duplex containing a (6–4) photoproduct, as
described elsewhere (45), using cell-free extracts prepared from p53/ and
p53/Cry1/Cry2/ primary fibroblasts that were supplemented with re-
combinant RPA. The excision levels were quantified using ImageQuant 5.2
software (Molecular Dynamics).
DNA Damage Checkpoint and Apoptosis Assays. For apoptosis analysis using
caspase 3 cleavage, cells were treated with 10 J/m2 UV dose, and incubated for
24 h. For apoptosis analysis using PARP cleavage, cells were treated with 10, 20,
50 J/m2 UV doses and incubated for 24 h. For checkpoint response, cells were
treated with 10 J/m2 UV dose and incubated for 2 h. For estimating Wee1
levels, phosphorylation status of Chk1 and Chk2, and proteolytic cleavage of
caspase 3 and PARP, 50 g of protein from total cell lysates were used for
immunoblotting with the appropriate antibodies. Rabbit polyclonal anti-
Wee1 (H-300), goat polyclonal anti-actin, rabbit polyclonal anti-p53, and
anti-IgG goat-HRP conjugates were obtained from Santa Cruz Biotechnology.
Rabbit polyclonal anti-phospho-ser345-Chk1, anti-phospho-thr68-Chk2,
cleaved caspase 3, and PARP antibodies were from Cell Signaling Technology,
anti-IgG rabbit-HRP conjugates were from GE HealthCare, and rabbit poly-
clonal anti-Cry2 was from Alpha Diagnostic International. Rat monoclonal
anti-Cry1 (IgM) antibody was produced in our laboratory (15).
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Fig. 7. Analyses of p53-KO and TRI-KO fibroblasts for cell cycle regulation,
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